COUR Pharmaceuticals Secures $40M Upfront in Genentech Deal, Potential Milestones Exceed $900M

Chicago, December 3, 2024 (Globe Newswire) -- COUR Pharmaceuticals and Genentech have partnered to develop novel autoimmune disease treatments using COUR's tolerogenic nanoparticle platform. COUR will earn $40 million upfront and may receive over $900 million in additional milestones and royalties. The collaboration combines COUR’s innovation with Genentech’s expertise in clinical development and commercialization.

Read full article here.